Psychiatry

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.

Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily lives.

Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.

This segment of Hemming’s ACP interview featured a discussion of a website used to assess digital applications for patients struggling with mental health issues.

NBI-1065845 shows promise in alleviating symptoms of major depressive disorder in patients with inadequate response to current antidepressant treatments, according to phase 2 SAVITRI study data.

Shah discusses the prevalence of psychiatric illness among hospitalized patients and highlights key considerations for their management from her session at ACP.

This interview at ACP 2024 featured a discussion with Hemming on the Mental Health Care Model (MHCM) and addressing depression in primary care settings.

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

Vision issues were linked to an increased risk of suicidal ideation, suicidal behavior, and suicide death, particularly among adolescents.

In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

In an interview with HCPLive, Sunny Rai, PhD, shed light on a new study regarding how an AI model failed to detect depression in Black individuals.

A new study found extending postpartum Medicaid from 60 days to 12 months is linked to new mothers being more likely to seek mental health care for perinatal mood and anxiety disorders.

A new study found a single low dose of esketamine given shortly after childbirth reduced major depressive episodes at 42 days postpartum by about 3 quarters.

Patients on psilocybin for depression or anxiety reported tolerable adverse events, including headache, nausea, anxiety, dizziness, and elevated blood pressure.

Sibling control analyses showed acetaminophen use during pregnancy was not associated with an offspring’s risk of autism, ADHD, or intellectual disability.

A study using machine learning models found “I” usage on Facebook posts does not predict depression severity in Black individuals.

EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.

A new study showed how taking alcohol use disorder medication following an alcohol-related hospitalization discharge was linked to a reduction in return to hospital in 30 days.

Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.